Colorectal cancer (CRC) is the third most common cancer in both men and women, and the third most common cause of cancer-related death in the UK and the US [1]. Men have a lifetime probability of developing CRC of approximately 6%, and women have a lifetime probability of approximately 5% [1]. Early diagnosis of CRC relies on screening, with colonoscopy and fecal occult blood testing being the most commonly used screening methods. When CRC is diagnosed after symptoms have occurred, the disease may be more advanced, and cure cannot be guaranteed despite recent significant advances in treatment.